Página principal > Resultados de la búsqueda: Papp, Kim A.
  Consejos para la búsqueda
Búsqueda avanzada
Buscar colecciones:
Ordenar por: Mostrar resultados: Formato de visualización:
Resultados globales: 7 registros encontrados en 0.02 segundos.
Artículos, Encontrados 7 registros
Artículos Encontrados 7 registros  
1.
10 p, 1.7 MB Matching-adjusted indirect comparison of efficacy outcomes in trials of calcipotriol plus betamethasone dipropionate foam and cream formulations for the treatment of plaque psoriasis / Papp, Kim A (K Papp Clinical Research) ; Thoning, Henrik (LEO Pharma) ; Gerdes, Sascha (Center for Inflammatory Skin Diseases. Dept. of Dermatology. Venereology and Allergology. University Medical Center Schleswig-Holstein) ; Megna, Matteo (Section of Dermatology. Dept. of Clinical Medicine and Surgery. University of Naples Federico II) ; Brandi, Henrik (LEO Pharma) ; Jablonski Bernasconi, Marie Y. (LEO Pharma) ; Yélamos, Oriol (Institut d'Investigació Biomèdica Sant Pau) ; Universitat Autònoma de Barcelona
Background and objectives: Once-daily, fixed-combination calcipotriol 50 μg/g (Cal) plus betamethasone dipropionate 0. 5 mg/g (BD) is available in aerosol foam and cream formulations. As no head-to-head data are available, we use a matching-adjusted indirect comparison (MAIC) approach to compare Cal/BD foam and cream. [...]
2022 - 10.1080/09546634.2022.2095330
Journal of Dermatological Treatment, Vol. 33 Núm. 7 (2022) , p. 3005-3013  
Registro completo - Creative Commons
2.
11 p, 1.5 MB Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis : interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up / Papp, Kim A (K Papp Clinical Research and Probity Medical Research) ; Lebwohl, M. G. (Icahn School of Medicine at Mount Sinai) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Ohtsuki, M. (Jichi Medical University) ; Beissert, Stefan (Department of Dermatology. University Hospital Carl Gustav Carus. TU Dresden) ; Zeng, J. (AbbVie Inc.) ; Rubant, S. (AbbVie Inc.) ; Sinvhal, R. (AbbVie Inc.) ; Zhao, Y. (AbbVie Inc.) ; Soliman, A.M. (AbbVie Inc.) ; Alperovich, G. (AbbVie Inc.) ; Leonardi, C. (Central Dermatology. Richmond Heights)
Background: Psoriasis is a chronic inflammatory skin disease requiring prolonged treatment. New biologic therapies require long-term evaluation to assess the durability of their efficacy and safety profiles over time. [...]
2021 - 10.1111/bjd.20595
British journal of dermatology, Vol. 185 Núm. 6 (december 2021) , p. 1135-1145  
Registro completo - Creative Commons
3.
16 p, 1.2 MB Deucravacitinib in Moderate to Severe Psoriasis : Clinical and Quality-of-Life Outcomes in a Phase 2 Trial / Thaçi, Diamant (University of Luebeck) ; Strober, Bruce (Yale University) ; Gordon, Kenneth B. (Medical College of Wisconsin) ; Foley, Peter (The University of Melbourne) ; Gooderham, Melinda (Queen's University and Probity Medical Research) ; Morita, Akimichi (Nagoya City University) ; Papp, Kim A. (Clinical Research and Probity Medical Research) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Menter, M. Alan (Baylor University Medical Center) ; Colombo, Matthew J. (Bristol Myers Squibb) ; Elbez, Yedid (Bristol Myers Squibb) ; Kisa, Renata M. (Bristol Myers Squibb) ; Ye, June (Bristol Myers Squibb) ; Napoli, Andrew A. (Bristol Myers Squibb) ; Wei, Lan (Bristol Myers Squibb) ; Banerjee, Subhashis (Bristol Myers Squibb) ; Merola, Joseph F. (Harvard Medical School) ; Gottlieb, Alice B. (Icahn School of Medicine at Mount Sinai) ; Universitat Autònoma de Barcelona
Deucravacitinib is an oral, selective tyrosine kinase 2 inhibitor that demonstrated therapeutic benefit in a Phase 2 clinical trial of adults with moderate to severe plaque psoriasis. This analysis was designed to evaluate the effect of deucravacitinib on additional clinical and quality-of-life (QoL) outcomes and assess the relationship between these outcomes in adults with psoriasis. [...]
2022 - 10.1007/s13555-021-00649-y
Dermatology and Therapy, Vol. 12 (january 2022) , p. 495-510  
Registro completo - Creative Commons
4.
14 p, 980.7 KB Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis : A Machine Learning Predictive Model / Papp, Kim A. (K Papp Clinical Research and Probity Medical Research) ; Soliman, Ahmed M. (AbbVie, Inc) ; Done, Nicolae (Analysis Group, Inc) ; Carley, Christopher (Analysis Group, Inc) ; Lemus Wirtz, Esteban (Analysis Group, Inc) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Universitat Autònoma de Barcelona
Risankizumab has demonstrated efficacy in treating moderate-to-severe psoriasis. The phase-3 IMMhance trial (NCT02672852) examined the effect of continuing versus withdrawing from risankizumab treatment on psoriasis severity, including the Psoriasis Area and Severity Index (PASI) and static Physician Global Assessment (sPGA). [...]
2021 - 10.1007/s13555-021-00550-8
Dermatology and Therapy, Vol. 11 (may 2021) , p. 1291-1304  
Registro completo - Creative Commons
5.
9 p, 310.0 KB Long-term safety and tolerability of apremilast in patients with psoriasis : Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2) / Crowley, Jeffrey (Bakersfield Dermatology) ; Thaçi, Diamant (Universitätsklinikum Schleswig-Holstein (Alemanya)) ; Joly, Pascal (Department of Dermatology, Hôpital Charles Nicolle, Université de Rouen) ; Peris, Ketty (Universitá Cattolica del Sacro Cuore, Roma) ; Papp, Kim A. (Probity Medical Research, Waterloo) ; Gonçalves, Joana (Celgene Corporation) ; Day, Robert M. (Celgene Corporation) ; Chen, Rongdean (Celgene Corporation) ; Shah, Kamal (Celgene Corporation) ; Ferrándiz, Carlos (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Cather, Jennifer C. (Modern Research Associates, Dallas) ; Universitat Autònoma de Barcelona
2017 - 10.1016/j.jaad.2017.01.052
Journal of the American Academy of Dermatology, Vol. 77 Núm. 2 (2017) , p. 310  
Registro completo - Creative Commons
6.
1 p, 320.3 KB Correction to : Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) / Blauvelt, Andrew (SW Locust St., Suite G, Portland, OR 97223 USA) ; Papp, Kim A. (Waterloo, Canada) ; Griffiths, Christopher E. M. (Manchester, UK) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Weisman, Jamie (Medical Dermatology Specialists, Inc., Atlanta, GA USA) ; Dutronc, Yves (Indianapolis, IN USA) ; Kerr, Lisa Farmer (Indianapolis, IN USA) ; Ilo, Dapo (Indianapolis, IN USA) ; Mallbris, Lotus (Indianapolis, IN USA) ; Augustin, Matthias (University Medical Center Hamburg-Eppendorf) ; Universitat Autònoma de Barcelona
2018 - 10.1007/s40257-018-0353-x
American Journal of Clinical Dermatology, Vol. 19 (march 2018) , p. 457  
Registro completo - Creative Commons
7.
8 p, 420.3 KB Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders : a Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) / Blauvelt, Andrew (SW Locust St., Suite G, Portland, USA) ; Papp, Kim A. (Waterloo, Canada) ; Griffiths, Christopher E. M. (Manchester, UK) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Weisman, Jamie (Medical Dermatology Specialists, Inc., Atlanta, GA USA) ; Dutronc, Yves (Indianapolis, IN USA) ; Kerr, Lisa Farmer (Indianapolis, IN USA) ; Ilo, Dapo (Indianapolis, IN USA) ; Mallbris, Lotus (Indianapolis, IN USA) ; Augustin, Matthias (University Medical Center Hamburg-Eppendorf) ; Universitat Autònoma de Barcelona
Patients with psoriasis who have an inadequate response to one biologic may benefit from switching to a new biologic, such as ixekizumab, a high affinity monoclonal antibody that selectively targets interleukin (IL)-17A. [...]
2017 - 10.1007/s40257-016-0246-9
American Journal of Clinical Dermatology, Vol. 18 (january 2017) , p. 273-280  
Registro completo - Creative Commons

Vea también: autores con nombres similares
1 Papp, K.
1 Papp, K. V.
1 Papp, K.A.
2 Papp, Kathryn V.
1 Papp, Kim
2 Papp, Kim A
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.
Depósito Digital de Documentos de la UAB :: Buscar :: Enviar :: Personalizar :: Ayuda
Powered by Invenio v1.1.6
Mantenido por ddd.bib@uab.cat  :: Metadatos sujetos a:
Colaboramos